Bob More brings 30 years of life sciences investing experience.

Bob currently serves on the board of Amplitude Therapeutics, Inc., Kelonia Therapeutics, (acquisition announced by Eli Lilly) MBrace Therapeutics, Tyra Biosciences (NASDAQ: TYRA), Variant Bio, eGenesis, Vir Biotechnology, Inc (NASDAQ: VIR) and SciThera. He was a founding board member of the Kauffman Fellows Program and previously served on the board of BIO (Biotechnology Innovation Organization).

Prior to Alta, Bob was a Senior Advisor for the Bill and Melinda Gates Foundation. Prior to that, Bob spent 5 years as a General Partner at Frazier Healthcare Ventures and 13 years at Domain Associates. Bob managed successful investments in and served on the boards of Affinivax (acquired by GSK), Cartiva (acquired by Wright Medical), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Glaukos Corporation (NYSE: GKOS), IntraLase (acquired by Advanced Medical Optics), NovaCardia (acquired by Merck), Oceana Therapeutics (acquired by Salix Pharmaceuticals), Proxima Therapeutics (acquired by Cytyc Corporation) and Kelonia, Bob is also an investor in Encoded Therapeutics and Zeltiq Aesthetics (acquired by Allergan).

He received his B.A. from Middlebury College and an M.B.A. from Darden at the University of Virginia.